Procaps Group Future Growth

Future criteria checks 1/6

Procaps Group's earnings are forecast to decline at 6.1% per annum while its annual revenue is expected to grow at 9.7% per year. EPS is expected to decline by 23.2% per annum.

Key information

-6.1%

Earnings growth rate

-23.2%

EPS growth rate

Pharmaceuticals earnings growth	20.9%
Revenue growth rate	9.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Jan 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively

Mar 28

Earnings and Revenue Growth Forecasts

NasdaqGM:PROC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	519	48	N/A	N/A	1
12/31/2024	460	43	N/A	27	2
12/31/2023	424	54	N/A	36	2
9/30/2023	414	52	34	63	N/A
6/30/2023	406	67	-7	21	N/A
3/31/2023	408	33	-22	11	N/A
12/31/2022	410	43	-17	14	N/A
9/30/2022	435	60	-22	8	N/A
6/30/2022	431	-73	7	37	N/A
3/31/2022	418	-67	9	34	N/A
12/31/2021	410	-101	13	37	N/A
9/30/2021	401	-119	58	92	N/A
6/30/2021	374	-9	39	60	N/A
3/31/2021	342	-18	49	67	N/A
12/31/2020	331	-10	53	71	N/A
1/1/2020	325	-17	56	68	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROC's earnings are forecast to decline over the next 3 years (-6.1% per year).

Earnings vs Market: PROC's earnings are forecast to decline over the next 3 years (-6.1% per year).

High Growth Earnings: PROC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PROC's revenue (9.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: PROC's revenue (9.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PROC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Procaps Group Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 28%

Price target increased to US$13.00

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Recent updates

These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively

Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives

Investor sentiment deteriorates as stock falls 23%

Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?

New major risk - Revenue and earnings growth

Hoche Partners Sends a Letter to Procaps Group

Hoche Partners Sends a Letter to Procaps Group

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 19%

Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024

Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024

Investor sentiment deteriorates as stock falls 17%

Procaps Group S.A. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Procaps Group S.A. Appoints Sandra Sanchez Y Oldenhage as A Director

Investor sentiment deteriorates as stock falls 19%

Second quarter 2023 earnings released: EPS: US$0.27 (vs US$0.068 loss in 2Q 2022)

Procaps Group S.A. to Report Q2, 2023 Results on Sep 05, 2023

Procaps Group S.A., Annual General Meeting, Jun 30, 2023

Procaps Group S.A. to Report Q1, 2023 Results on Jun 05, 2023

Consensus EPS estimates fall by 28%

Full year 2022 earnings released: EPS: US$0.42 (vs US$1.03 loss in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 15%

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Procaps Group S.A. Announces Board Changes

Procaps Group S.A. (NasdaqGM:PROC) announces an Equity Buyback for 2,000,000 shares, for $5 million.

Now 22% undervalued after recent price drop

Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)

Investor sentiment deteriorates as stock falls 16%

Procaps Group Announces Key Changes to the Board of Directors

Price target increased to US$13.00

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released

Procaps Group S.A. to Report Q3, 2022 Results on Nov 14, 2022

Now 22% undervalued after recent price drop

Now 23% undervalued after recent price drop

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.01 loss in 2Q 2021)

Procaps Group reports Q2 results

Now 20% undervalued after recent price drop

First quarter 2022 earnings released: EPS: US$0.16 (vs US$0.18 loss in 1Q 2021)

Procaps Group S.A., Annual General Meeting, Jun 28, 2022

Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation.

Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation.

Forecast to breakeven in 2022

Now 20% undervalued after recent price drop

Forecast to breakeven in 2022

Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director

Procaps Group, S.A. (NasdaqGM:PROC) acquired 86,000 sq. ft. Pharmaceutical Production Facility Located in West Palm Beach, Florida from Strides Pharma Inc.

Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies